FIT Biotech Oy
Company Release January 21, 2016 at 8.30 EET
Changes in FIT Biotech's Management team and Board of Directors
Mr Andres Männik (43), Ph.D. has been appointed as Chief Scientific Officer and member of Management Team of the Finnish biotechnology company FIT Biotech as of January 20, 2016. Mr Männik has been employed by FIT Biotech earlier in 2000-2011 as Senior Scientist specializing in GTU-technology. Since 2011, Mr Männik has been employed by Estonian Icosagen Cell Factory OÜ that used to be associated company of FIT Biotech. The current Chief Scientific Officer, Professor Mart Ustav will continue his valued work with the company as a member of the Scientific Advisory Board.
The Chairman of the Board of Directors of FIT Biotech Oy, Mr Rabbe Slätis has been acting also as the CEO of the company since January 1, 2016 when Mr Kalevi Reijonen retired from the position. Mr Slätis will now withdraw from the position of the Chairman of the Board and will continue as board member. Mr Juha Vapaavuori, M.Sc., Vice Chairman of the Board will act as Chairman of the Board as of January 20, 2016.
FIT BIOTECH OY
Board of Directors
CEO, FIT Biotech Oy
Tel: +358 (0) 40 840 6749
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA vaccines and gene therapy. The company bases its products on its patented GTU® (Gene Transport Unit) technology.
Through GTU® technology, FIT Biotech develops DNA-based therapeutics in order to both prevent and also treat various diseases. Identified application areas include HIV, tuberculosis (and other infectious diseases) as well as gene therapy (cancer, autoimmune diseases). Other application areas are under development.
FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More information can be found at www.fitbiotech.com.
NASDAQ OMX Helsinki